liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
Department of Pathology, Uppsala University Hospital, Sweden.
Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Onkologiskt centrum. Linköpings universitet, Hälsouniversitetet.
Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
Vise andre og tillknytning
2011 (engelsk)Inngår i: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 126, nr 2, s. 421-430Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early-stage invasive breast cancer. The Stockholm Breast Cancer Study Group conducted a randomized trial during 1976 through 1990 comparing adjuvant tamoxifen versus control. The patients were stratified according to tumor size and lymph node status in high-risk and low-risk groups. In this study we evaluated 683 patients with “low risk” breast cancer (size ≤30 mm, lymph node-negative) for whom ER status had been determined by both the cytosol assays and IHC at one pathology laboratory. The median follow-up was 17 years. Six hundred eighty-three patients had tumors with ER determined by both methods, 536 (78.5%) were ER-positive by cytosol assays using the cutoff level at ≥0.05 fmol/μg DNA and 539 patients were ER-positive (79%) by IHC using the cutoff level at ≥10% cell stained. Thirty-nine tumors (5.7%) were ER-positive by cytosol but not by IHC, whereas the opposite pattern was found for 42 cases (6.1%). Only seven tumors had stained cells between 0 and 9% by IHC. The concordance between IHC and cytosol assays was high (88%). The kappa statistic was 0.65, 95% CI 0.58–0.72. Among patients classified as ER-negative no therapeutic benefit from tamoxifen was observed. Among patients with ER-expressing tumors, tamoxifen resulted in significantly better recurrence-free survival irrespective of the method (IHC: HR, 0.53, P < 0.001; cytosol: HR, 0.53, P < 0.001). The effect on overall survival was not statistically significant probably due to the limited sample size. Both IHC and cytosol assay accurately predict long-term response to adjuvant tamoxifen.

sted, utgiver, år, opplag, sider
Springer Science Business Media , 2011. Vol. 126, nr 2, s. 421-430
Emneord [en]
Breast cancer, Estrogen receptor, Tamoxifen, Cytosol, Immunohistochemical
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-67030DOI: 10.1007/s10549-010-1202-7ISI: 000288251000014OAI: oai:DiVA.org:liu-67030DiVA, id: diva2:406281
Tilgjengelig fra: 2011-03-25 Laget: 2011-03-25 Sist oppdatert: 2017-12-11

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Fohlin, HelenaStål, OlleNordenskjöld, Bo

Søk i DiVA

Av forfatter/redaktør
Fohlin, HelenaStål, OlleNordenskjöld, Bo
Av organisasjonen
I samme tidsskrift
Breast Cancer Research and Treatment

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 124 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf